Robert W. Baird Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its target price lowered by analysts at Robert W. Baird from $103.00 to $100.00 in a report issued on Wednesday, MarketBeat reports. The brokerage presently has a “neutral” rating on the medical technology company’s stock. Robert W. Baird’s price target points to a potential upside of 2.47% from the company’s current price.

Other analysts have also issued reports about the company. UBS Group restated a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. Daiwa Securities Group boosted their target price on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Morgan Stanley upped their price target on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. lifted their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Finally, Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $111.05.

Medtronic Trading Down 0.9%

NYSE:MDT opened at $97.59 on Wednesday. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market capitalization of $125.10 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 2.60 and a beta of 0.71. The business’s 50-day simple moving average is $99.10 and its 200-day simple moving average is $96.60.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the prior year, the business earned $1.38 EPS. Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts expect that Medtronic will post 5.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Delos Wealth Advisors LLC acquired a new position in Medtronic during the second quarter worth approximately $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the 3rd quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the 4th quarter worth approximately $27,000. Anfield Capital Management LLC raised its stake in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the period. Finally, Valley Wealth Managers Inc. acquired a new stake in Medtronic during the 3rd quarter valued at $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic reported $1.36 EPS vs. $1.34 consensus and $9.02B revenue vs. $8.89B expected; company cited robust demand for heart devices, which supports near-term earnings and the company’s FY26 guidance. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Robotics and cardiovascular growth runway — analysts (e.g., TD Cowen) continue to highlight multi‑year growth potential from cardiovascular and robotics pipelines and have reiterated buy/outperform views, supporting upside vs. peers. Medtronic: Sustained Outperformance and Multi‑Year Growth Runway
• Neutral Sentiment: Earnings call / transcript available — investors can review management’s commentary on guidance, margin outlook and device demand to assess sustainability of the beat. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst commentary is mixed — media coverage highlights divergent analyst views on Medtronic vs. peers (e.g., Globe and Mail pieces), reflecting differing weight on growth vs. risk. Analysts Conflicted on These Healthcare Names: Masimo (MASI) and Medtronic (MDT)
• Negative Sentiment: Analysts trimmed targets and forecasts after Q3 — several firms cut price targets (JPMorgan and Baird to ~$100; Leerink and others trimmed slightly) and lowered near‑term forecasts, which reduces sell‑side upside and can pressure the stock. Medtronic Analysts Cut Their Forecasts After Q3 Earnings JPMorgan adjusts price target on Medtronic
• Negative Sentiment: Legal/competitive overhang noted — coverage of Q3 calls out a “legal hit” and competitive pressure in certain device areas; these risks can weigh on multiples until resolved. Is Mixed Q3 Results, Robotics Win and Legal Hit Altering The Investment Case For Medtronic (MDT)?

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).